Armata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy #USA #Los_Angeles #Armata_Pharmaceuticals #AP-SA02 #antimicrobial_therapy
@newsen.bsky.social@newsen.bsky.social
@newsen.bsky.socialArmata Pharmaceuticals Secures $3.7 Million for Phase 3 Development of Antibiotic-Resistant Therapy #USA #Los_Angeles #Armata_Pharmaceuticals #AP-SA02 #antimicrobial_therapy